ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Clinical-pharmacological medication reviews for insurants of a German statutory health insurance fund (Kaufmännische Krankenkasse (KKH)): a 5-year retrospective analysis (2019-2023).
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study sought to evaluate the characteristics of clinical-pharmacological (CP) medication reviews conducted by the Institute for Clinical Pharmacology of Hannover Medical School for older, multimorbid, polymedicated insurants of the German statutory health insurance fund Kaufmännische Krankenkasse (KKH). Special emphasis was put on potential sex-specific differences between female and male insurants, prescriptions of potentially inappropriate medications for older individuals (PIMs), and potentially inappropriate duplicate prescriptions (PIDPs). Medication reviews conducted for KKH insurants between 2019 and 2023 (n = 334) were analyzed retrospectively. Clinical trial number is not applicable. The median age of KKH insurants (58.1% female) was 74 years (first quartile (Q1): 68; third quartile (Q3): 80). Insurants displayed a median of 7 diseases (Q1: 5; Q3: 9) and took a median of 13 drugs (Q1: 11; Q3: 16). A median of 4 CP recommendations was issued per medication review (Q1: 3; Q3: 5). The number of CP recommendations was significantly higher for female compared to male insurants (median of 4 (Q1: 3; Q3: 6) vs. median of 3 recommendations (Q1: 2; Q3: 4); p < 0.001), while the number of drugs was identical and the number of diagnoses was higher for female insurants. The most frequently prescribed PIMs were tricyclic antidepressants, benzodiazepines, and Z-drugs. At least one PIDP was detected in 16.5% of medication reviews. The sex-specific difference in the number of CP recommendations between female and male insurants may point to an unmet pharmacotherapeutic need in older women. PIM prescriptions and PIDPs were relevant topics of CP recommendations, suggesting possibilities for pharmacotherapeutic optimization in older, multimorbid, polymedicated patients.
Indexed as
Identifiers
42484864What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.